Hybio Pharmaceutical Hits Day High with Strong 3.4% Intraday Surge

Hybio Pharmaceutical Co. has experienced a notable increase of 3.4% on March 24, 2026, reaching an intraday high of CNY 18.05. This performance stands out against the backdrop of the China Shanghai Composite, which recorded a gain of 1.78% on the same day. Over the past year, Hybio has shown a robust performance with a 31.43% increase, significantly outperforming the broader market index, which only rose by 15.17%. However, the company has faced challenges in the short term, with a 1.75% decline over the past week and a 1.54% drop in the last month. Despite these fluctuations, Hybio's long-term performance remains impressive, with a 236.59% increase over the past five years. The company operates within the Pharmaceuticals & Biotechnology sector and holds a market capitalization of CNY 12,188 million. However, it is important to note that Hybio is currently facing operational losses and has a high debt-to-equity ratio of 2.76, indicating potential financial risks.